These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22894957)

  • 21. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
    Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
    J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.
    Verardi PH; Titong A; Hagen CJ
    Hum Vaccin Immunother; 2012 Jul; 8(7):961-70. PubMed ID: 22777090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
    Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
    Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
    Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
    Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
    Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
    J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
    Drexler I; Staib C; Sutter G
    Curr Opin Biotechnol; 2004 Dec; 15(6):506-12. PubMed ID: 15560976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
    Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
    J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
    Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
    Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
    Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.
    Ourmanov I; Brown CR; Moss B; Carroll M; Wyatt L; Pletneva L; Goldstein S; Venzon D; Hirsch VM
    J Virol; 2000 Mar; 74(6):2740-51. PubMed ID: 10684290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.
    Sliva K; Martin J; von Rhein C; Herrmann T; Weyrich A; Toda M; Schnierle BS
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.
    Earl PL; Americo JL; Wyatt LS; Eller LA; Montefiori DC; Byrum R; Piatak M; Lifson JD; Amara RR; Robinson HL; Huggins JW; Moss B
    Virology; 2007 Sep; 366(1):84-97. PubMed ID: 17499326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
    Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
    Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model.
    Kreijtz JH; Süzer Y; Bodewes R; Schwantes A; van Amerongen G; Verburgh RJ; de Mutsert G; van den Brand J; van Trierum SE; Kuiken T; Fouchier RA; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Gen Virol; 2010 Nov; 91(Pt 11):2745-52. PubMed ID: 20719991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Equination (inoculation of horsepox): An early alternative to vaccination (inoculation of cowpox) and the potential role of horsepox virus in the origin of the smallpox vaccine.
    Esparza J; Schrick L; Damaso CR; Nitsche A
    Vaccine; 2017 Dec; 35(52):7222-7230. PubMed ID: 29137821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene
    Chea LS; Wyatt LS; Gangadhara S; Moss B; Amara RR
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.
    Brandler S; Lepelley A; Desdouits M; Guivel-Benhassine F; Ceccaldi PE; Lévy Y; Schwartz O; Moris A
    J Virol; 2010 May; 84(10):5314-28. PubMed ID: 20219934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.
    Van Rompay KK; Abel K; Earl P; Kozlowski PA; Easlick J; Moore J; Buonocore-Buzzelli L; Schmidt KA; Wilson RL; Simon I; Moss B; Rose N; Rose J; Marthas ML
    Vaccine; 2010 Feb; 28(6):1481-92. PubMed ID: 19995539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.